 Anacetrapib (Merck & Co., Inc.) is a cholesteryl ester transfer protein (CETP) inhibitor that blocks the transfer of cholesterol from high-density lipoprotein to other lipoproteins. This results in an increase in high-density lipoprotein cholesterol (HDL-C) and a decrease in low-density lipoprotein cholesterol (LDL-C), which may reduce the development of atherosclerosis. Anacetrapib has not b...

To investigate the effects of chronic ethanol administration on the mobilization and excretion of cholesterol, turnover and balance studies were carried out in baboons pair-fed cholesterol-free diets containing 50% of energy either as ethanol or as additional carbohydrate for several years. Ethanol feeding increased free cholesterol in all plasma lipoprotein fractions, and esterified cholestero...

Density gradient centrifugation was used to characterize the lipoprotein distribution of rhesus monkeys and human subjects with normal and elevated cholesterol levels. The lipoprotein profile of control monkeys differed from that of normal humans in that their density distribution as a whole was shifted to lower density. The most striking difference was that both rhesus high density lipoprotein...

Background: Type II diabetes mellitus (DM) is characterized by insulin resistance such as glucose intolerance, dyslipidemia, and hypertension, results in an increased predisposition to atherosclerotic vascular disease. The present study was conducted evaluate fasting postprandial lipid profile diabetic patients. Materials & Methods: We put 80 type patients group I healthy subjects II. Parameter...

Cultured extrahepatic cells possess a specific high affinity receptor for high density lipoprotein (HDL) that is induced by cholesterol delivery to cells. Current results suggest that HDL receptors on cultured human fibroblasts and mouse peritoneal macrophages promote reversible binding of HDL to the cell surface without internalization of lipoprotein particles. When 125I-HDL3 was bound to cult...

Low-density lipoprotein (LDL) cholesterol concentration has been the prime index of cardiovascular disease risk and the main target for therapy. However, several lipoprotein ratios or "atherogenic indices" have been defined in an attempt to optimize the predictive capacity of the lipid profile. In this review, we summarize their pathophysiological aspects, and highlight the rationale for using ...

Epidemiologic studies have shown that the concentration of high-density lipoprotein cholesterol (HDL-C) is a strong, independent, inverse predictor of coronary heart disease risk. This identifies HDL-C as a potential therapeutic target. Compared with low-density lipoprotein cholesterol (LDL-C)-lowering agents, however, currently available HDL-raising drugs are relatively ineffective. Consequent...

BACKGROUND Changes in conventional lipid risk factors with gemfibrozil treatment only partially explain the reductions in coronary heart disease (CHD) events experienced by men in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). We examined whether measurement of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle subclasses provides additional in...

Background: Dyslipidemia is a lipid metabolism disorder that causes changes in plasma lipoprotein function and/or levels of Triglycerides (TG), total cholesterol (TC), Low-Density Lipoprotein (LDL), and High-Density (HDL). Administration Medium Chain Triglyceride (MCT) non-pharmacological therapy effectively improves profiles reduces the risk dyslipidemia. Objectives: This study aimed to conduc...